Brief: Lexicon To Present Preclinical In Vivo Efficacy Data Demonstrating Ability Of New Investigational Compound To Enhance And Maintain Semaglutide-Promoted Weight Loss
04/11/2024 14:28
Nov 4 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O :
* LEXICON TO PRESENT PRECLINICAL IN VIVO EFFICACY DATA
DEMONSTRATING ABILITY OF NEW INVESTIGATIONAL COMPOUND TO ENHANCE
AND MAINTAIN SEMAGLUTIDE-PROMOTED WEIGHT LOSS
Source text: ID:nGNX4jgMPd
Further company coverage: LXRX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview